Loading...
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
Barros-Martins, Joana Hammerschmidt, Swantje I Cossmann, Anne Odak, Ivan Stankov, Metodi V Morillas Ramos, Gema Dopfer-Jablonka, Alexandra Heidemann, Annika Ritter, Christiane Friedrichsen, Michaela
Barros-Martins, Joana
Hammerschmidt, Swantje I
Cossmann, Anne
Odak, Ivan
Stankov, Metodi V
Morillas Ramos, Gema
Dopfer-Jablonka, Alexandra
Heidemann, Annika
Ritter, Christiane
Friedrichsen, Michaela
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-07-14
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 8.42 MB
Other Titles
Abstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.
Citation
Barros-Martins, J., Hammerschmidt, S.I., Cossmann, A. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med 27, 1525–1529 (2021). https://doi.org/10.1038/s41591-021-01449-9
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1546-170X
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International